General Information
Version
6.6
Revision date
2023-03-17
Product name
Nitrilotriacetic acid
CAS No.
139-13-9
REACH No
01-2119471481-40-XXXX
Emergency telephone
+56 2 2581 4934
Icons in SDS
Company Information
company name
Merck S.A
e-mail address of the competent person responsible for the Safety Data Sheet
atencionclientes@merckgroup.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H302, H319, H351
Hazard statements
Code
Statements
H302
Harmful if swallowed
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008] Classification of the substance or mixture
Signal word
Warning Warning
Hazard statements
H302 Harmful if swallowed. H319 Causes serious eye irritation. H351 Suspected of causing cancer. H351 Suspected of causing cancer.
Precautionary statements
P202 Do not handle until all safety precautions have been read and understood. P264 Wash skin thoroughly after handling. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P301 + P312 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Supplemental label elements
none Reduced Labeling (<= 125 ml) none
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher
2.1 Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 Acute toxicity, Oral (Category 4), H302 Eye irritation (Category 2), H319 Carcinogenicity (Category 2), H351 For the full text of the H-Statements mentioned in this Section, see Section 16.
